AstraZeneca PLC (AZN.LN) said on Monday that the Phase 2 trial for Enhertu, its gastric cancer drug, met its primary endpoint.
The U.K. pharmaceutical company said the trial met the primary
endpoint of objective response rate and key secondary endpoint of
overall survival in patients with previously treated HER2-positive
metastatic gastric cancer compared to an investigator’s choice of
chemotherapy.
“Given the previous results seen in our HER2-positive development
program and now in HER2-positive metastatic gastric cancer, we believe
this antibody drug conjugate has the potential to redefine the treatment
of patients with HER2-expressing cancers,” the company said.
https://www.marketscreener.com/ASTRAZENECA-4000930/news/AstraZeneca-Enhertu-Phase-2-Trial-Meets-Primary-Endpoint-29894270/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.